Human CD137 / 4-1BB / TNFRSF9 Protein (His Tag)

Catalog Number: 10041-H08H

General Information

Gene Name Synonym:
4-1BB; CD137; CDw137; ILA

Protein Construction:
A DNA sequence encoding the human 4-1BB extracellular domain (NP_001552.2) (Met 1-Qln 186) was fused with a polyhistidine tag at the C-terminus.

Source: Human

Expression Host: HEK293 Cells

QC Testing

Purity: > 95 % as determined by SDS-PAGE

Bio Activity:
1. Measured by its binding ability in a functional ELISA. 2. Immobilized human TNFRSF9 (Cat:10041-H08H) at 10μg/mL (100μL/well) can bind human TNFSF9 (Cat:15693-H01H), the EC50 of human TNFSF9 is 7-40ng/mL.

Endotoxin:
< 1.0 EU per μg of the protein as determined by the LAL method

Stability:
Samples are stable for up to twelve months from date of receipt at -70 °C

Predicted N terminal: Leu 24

Molecular Mass:
The recombinant human 4-1BB consists of 174 amino acids and has a calculated molecular mass of 18.8 kDa. By SDS-PAGE under reducing conditions, the apparent molecular mass of rh4-1BB is approximately 33-36 kDa due to glycosylation.

Formulation:
Lyophilized from sterile PBS, pH 7.4

Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. Please contact us for any concerns or special requirements.

Usage Guide

Storage:
Store it under sterile conditions at -20 °C to -80 °C upon receiving. Recommend to aliquot the protein into smaller quantities for optimal storage.

Avoid repeated freeze-thaw cycles.

Reconstitution:
Detailed reconstitution instructions are sent along with the products.

SDS-PAGE:

Protein Description

CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. Upon ligand binding, 4-1BB is associated with the tumor necrosis factor receptor–associated factors (TRAFs), the adaptor protein which mediates downstream signaling events including the activation of NF-kappaB and cytokine production. 4-1BB signaling either by binding to 4-1BBL or by antibody ligation delivers signals for T-cell activation and growth, as well as monocyte proliferation and B-cell survival, and plays an important role in the amplification of T cell-mediated immune responses. In addition, CD137 and CD137L are expressed in different human primary tumor tissues, suggesting that they may influence the progression of tumors. Crosslinking of CD137 on activated T cells has shown promise in enhancing anti-tumor immune responses in murine models, and agonistic anti-CD137 antibodies are currently being tested in phase I clinical trials.

References